跳至主要内容
临床试验/NCT00836524
NCT00836524Unknown不适用

"Kan IUGR og præeclampsi Forudsiges ud Fra YKL-40 målt i Serum?" "Metoder Til at Vurdere om Den Gravide Har Risiko for at Udvikle Svangerskabsforgiftning og/Eller væksthæmning Hos Fosteret".

Zealand University Hospital1 个研究点 分布在 1 个国家目标入组 2,000 人开始时间: 2009年1月最近更新:
适应症

试验速览

阶段
不适用
入组人数
2,000
试验地点
1

研究概览

简要总结

Objective: To investigate the role of maternal serum YKL-40 and uterine artery doppler, at gestational age 12, 20, 25 and 32 weeks, and the relation to preeclampsia and intrauterine growth restriction. The serum marker YKL-40 is related to conditions involving inflammation, infection, tissue remodeling, fibrosis and cancer. IUGR and preeclampsia are known to be related to inflammation and tissue remodeling.

Methods: women attending screening for downs syndrome is scanned with uterine artery doppler and delivered blood samples at GA 12, 20, 25 and 32 respectively. When pregnancy outcome is registered by medical records blood samples are retrieved and analyzed for serum YKL-40. Serum YKL-40 are correlated to the presence of bilateral notching, preeclampsia and different degrees of intrauterine growth restriction.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 50 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Pregnant danish speeking women

排除标准

  • Conditions/diseases involving chronical inflammation, or immunological activity

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Dorte Nymark Brask

MD, phd student

Zealand University Hospital

研究点 (1)

Loading locations...

相似试验